Regeneron Pharmaceuticals' Careers NewsEmployer Directory Featured Listing, Feeds and Subscriptions

The latest Regeneron Pharmaceuticals careers news and job posts. Subscribe for daily updates to your inbox, mobile device and/or smartphone.

  Jobs Feed | Subscribe  

Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Rege...
Posted: February 16, 2019, 8:10 am
Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Rege...
Posted: February 16, 2019, 8:10 am
Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Rege...
Posted: February 16, 2019, 8:10 am
Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Rege...
Posted: February 16, 2019, 8:10 am
Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Rege...
Posted: February 16, 2019, 8:10 am

Viewing page 1 of 98|Next Page

  Newsfeed | Subscribe  

Regeneron Pharmaceuticals (NASDAQ:REGN) and development partner Sanofi (NASDAQ:SNY) announce that the USPTO has invalidated 17 claims as obvious of U.S. Patent No. 8,679,487 owned by Amgen's ...
Posted: February 16, 2019, 7:43 am
Recap of the Week’s Top Stories: Earnings in Focus: Regeneron Pharmaceuticals (REGN - Free Report) delivered impressive results in the fourth quarter of 2018, wherein both earnings and sales beat esti...
Posted: February 13, 2019, 11:40 am
Sanofi SNY and partner Regeneron Pharmaceuticals, Inc. REGN announced a 60% cut in the U.S. list price of their PCSK9 inhibitor, Praluent, following a similar action last year by rival Amgen ...
Posted: February 12, 2019, 6:48 am
Regeneron Pharmaceuticals could increase its capital expenditures by more than $100 million this year. The manufacturer of bulk medications for treating skin cancer, eye disease and asthma plans to in...
Posted: February 12, 2019, 4:36 am
Get all the latest industry news in your inbox. Regeneron Pharmaceuticals and Sanofi today announced that Praluent (alirocumab) will be available at a new reduced price of $5,850 annually. This is a 6...
Posted: February 11, 2019, 11:43 am

Viewing page 1 of 3|Next Page